期刊文献+

重组人酸性成纤维细胞生长因子的稳定性研究 被引量:3

The stability of recombinant human acid fibroblast growth factor
在线阅读 下载PDF
导出
摘要 目的研究重组人酸性成纤维细胞生长因子(rhaFGF)在不同温度下的存放稳定性。方法rhaFGF冻干粉和溶媒在4,25和37℃分别保存30个月;rhaFGF液体在4℃保存56d,在25和37℃分别保存35d。采用MTT法测定rhaFGF的生物活性,同时进行外观性状、水分含量、pH值的测量和无菌试验。结果4℃时,rhaFGF冻干粉、液体和溶媒的各项性质在观察期内都无变化。25℃时,rhaFGF冻干粉、液体的生物活性分别在存放18个月和35d有下降趋势。37℃时,rhaFGF冻干粉、液体的生物活性分别在存放12个月和35d有下降趋势。结论rhaFGF冻干粉在4℃时可有效保存2年;rhaFGF冻干粉溶解后于4℃时保存28d内使用有效;溶媒在4℃时保存2年质量稳定。 OBJECTIVE To study the stability of recombinant human acid fibroblast growth factor (rhaFGF) deposited at 4℃, 25℃ or 37℃. METHODS The freeze-dried powder of rhaFGF and dissolvent were deposited at 4℃, 25℃ and 37℃ for 36 months. The solution of rhaFGF powder was deposited for 56 days at 4℃ and for 35 days at 25℃ and 37℃ respectively. The bioactivity of rhaFGF was determined by MTT method, and the appearance, water content, pH and sterility test were also observed. RESULTS All properties of rhaFGF freeze-dried powder, rhaFGF solution and dissolvent were not altered during the observation period at 4℃. However, the bioactivity of rhaFGF freeze-dried powder and its solution decreased after storage for 18 months or 35 days at 25℃ respectively. The bioactivity of rhaFGF freeze-dried powder and its solution decreased after storage for 12 months or 35 days at 37℃ respectively. CONCLUSION The freeze-dried powder rhaFGF and dissolvent can be deposited effectively for 2 years at 4℃. The solution of rhaFGF freeze-dried powder can be deposited effectively for 28 days at 4℃.
机构地区 暨南大学药学院
出处 《中国现代应用药学》 CAS CSCD 北大核心 2006年第5期358-360,共3页 Chinese Journal of Modern Applied Pharmacy
基金 国家863计划创新药物重大专项资助项目(No.2002AA2Z3318 No.2004AA2Z3C60) 广州市科技计划资助项目(No.2005J1-C0151)。
关键词 重组人酸性成纤维细胞生长因子 生物活性 稳定性 recombinant human acid fibroblast growth factor (rhaFGF) bioactivity stability
  • 相关文献

参考文献6

二级参考文献23

  • 1孙同柱,付小兵,孙晓庆,陈伟,程飚,李建福,赵志力.重组人酸性成纤维细胞生长因子促进皮肤缺损创面愈合的量效关系[J].中国组织工程研究与临床康复,2001,10(18):31-32. 被引量:19
  • 2薛沿宁,王会信.重组人酸性成纤维细胞生长因子的分离纯化及鉴定[J].生物化学与生物物理学报,1993,25(4):403-408. 被引量:3
  • 3戴宏,段莹莹.人实体瘤化疗敏感性试验MTT法影响因素的影响[J].苏州医学院学报,1996,16(5):868-870. 被引量:3
  • 4李翠玲,崔正言,李淑贞.MTT比色分析法的改良及初步应用[J].上海免疫学杂志,1996,16(5):306-307. 被引量:59
  • 5PANDIT A, ASHAR R, FELDMAN D, et al. Investigation of acidic fibroblast growth factor delivered through a collagen scaffold for the treatment of full- thickness skin defects in a rat model[J]. Plast Reconstr Surg , 1998 , 101(3) :766 - 775.
  • 6BJORNSSON T D, DRYJSKI M, TLUCZEK J, et al. Acidic fibroblast growth factor promotes vascular repair[J].Proc Natl Acad Sci USA, 1991,88(19) :8651- 8655.
  • 7MEIIJN T N, CASHEN D E, RONAN J J, et al. Acidic fibroblast growth factor accelerates dermal wound healing in diabetic mice[J]. J Invest Dermatol, 1995,104(5):850- 855.
  • 8MELLIN T N, MENNIE R J, CASHEN D E, et al. Acidic fibroblast growth factor accelerates dermal wound healing[J]. Growth Factors, 1992,7(1):1- 14.
  • 9WATANABE T, SENO M, SASADA R, et al. Molectdar characterization of recombinant human acidic fibroblast growth factor produced in E. coli: Comparative studies with human basic fibroblast growth factor[ J]. Mol Endocrinol, 1990,4(6) :869- 879.
  • 10BECERRIL C, PARDO A, MONTKNO M, et al. Acidic fibroblast growth factor induces an antitlbrogenic phenotypein human lung fibroblasts[J]. Am J Respir Cell Mol Biol, 1999,20(5) :1020 - 1027.

共引文献54

同被引文献42

  • 1王会岩,张耀方,万晓珊,解佳森,肖业臣,李校堃.人成纤维细胞生长因子-21分泌型表达及鉴定[J].吉林农业大学学报,2009,31(3):255-257. 被引量:9
  • 2马艳,金小宝,朱家勇.酸性成纤维细胞生长因子及其在创伤愈合中的应用[J].广东医学,2006,27(12):1918-1920. 被引量:14
  • 3支小毅,陈雪松,曾夏杏.EGF溶液治疗皮肤Ⅱ度创伤的药效观察[J].中国热带医学,2007,7(1):70-71. 被引量:1
  • 4Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease [J]. J Biochem, 2011, 149 (2) : 121-130.
  • 5Smith R, Duguay A, Weiszmann J, et al. A novel approach to improve the function of FGF21[J]. Biol Drugs, 2013,27 (2): 159-166.
  • 6Zhu WH, Wang CW, Wang HY, et al. Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo [J]. Can J Physiol Pharmaeol, 2014, 92 (11): 927- 935.
  • 7Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fihrohlast growth factor 21 (FGF21) -resistant state [J]. Diabetes, 2010, 59 (11): 2781-2789.
  • 8Zhang J, Li Y. Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome [J]. Drug Discov Today, 2014, 19 (5): 579-589.
  • 9Wang HY, Xiao YC, Li XK, et al. High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli [J ]. BMC Biotechnol, 2010, 10 (1): 14-23.
  • 10Brian MB, Bernhardt LT. Rational design of solution additives for the prevention of protein aggregation [J ]. Biophys J, 2004, 87 (3): 1631-1639.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部